New hope for kids with relapsed leukemia: drug combo trial launches
NCT ID NCT05645718
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a combination of chemotherapy drugs (mini-Hyper-CVD) plus three targeted therapies (rituximab, inotuzumab ozogamicin, and blinatumomab) in children and young adults with B-cell acute lymphocytic leukemia that has come back or not responded to treatment. The goal is to see if this approach can control the disease. About 27 participants will be enrolled, and the study monitors side effects as the main outcome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.